Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head randomized controlled trial.

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in stronger weight loss than semaglutide.

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.

Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, according to Eli Lilly (LLY).

Eli Lilly said on Wednesday patients on obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.

Eli Lilly & Co. Inc.’s stock rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s drug.

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical trial, Lilly said in a release Wednesday.